Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Blood and Tumor Samples From Men With an Inherited Risk of Prostate Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: August 13, 2009
Last updated: August 23, 2013
Last verified: August 2009

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify genes related to cancer.

PURPOSE: This clinical trial is studying blood and tumor samples from men with an inherited risk of prostate cancer.

Condition Intervention
Prostate Cancer
Other: laboratory biomarker analysis
Other: medical chart review
Other: questionnaire administration

Study Type: Observational
Official Title: UK Genetic Prostate Cancer Study

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Prostate cancer (PC) predisposition (PCP) genes [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Association of PCP genes with disease and treatment parameters [ Designated as safety issue: No ]
  • Association of PCP with environmental factors [ Designated as safety issue: No ]
  • Family history of PC [ Designated as safety issue: No ]
  • Relative risk of developing PC [ Designated as safety issue: No ]
  • Increased risk relatives of PC patients are to develop cancers other than PC [ Designated as safety issue: No ]
  • Markers of PC that are associated with PCP genes [ Designated as safety issue: No ]
  • Specific tumor genetic profile correlated with PCP genes [ Designated as safety issue: No ]

Estimated Enrollment: 21000
Study Start Date: June 1993
Detailed Description:


  • To find genes that predispose to prostate cancer (using genetic linkage and other molecular biology techniques).
  • To determine if genes that predispose to prostate cancer are associated with disease and treatment parameters.
  • To determine if genes that predispose to prostate cancer are associated with environmental factors.
  • To estimate the percentage of prostate cancer patients who have a positive family history of the disease.
  • To estimate the relative risk of developing prostate cancer in a currently unaffected member of a prostate cancer family.
  • To ascertain whether relatives of prostate cancer patients are at increased risk of developing cancers other than prostate cancer.
  • To build up a large blood and tumor (both fresh and preserved) bank from patients with prostate cancer to identify prostate cancer predisposition gene(s), determine the prevalence and penetrance of prostate cancer predisposition genes in prostate cancer patients, correlate changes in prostate cancer predisposition gene(s) with disease and treatment parameters by matching with clinical data from clinical databases already held as part of the medical record on these patients, and correlate changes in prostate cancer predisposition gene(s) with environmental factors collected by questionnaire from these patients.
  • To use the blood and tumor bank for marker studies (DNA, RNA, serum, plasma, protein, and other molecules) to define the role of these markers in disease prediction and progression.
  • To develop microarrays from prostate cancers to determine their genetic profile and correlate this with prostate cancer genetic predisposition genes.
  • To collect tissue from other unaffected and affected members of the family in cases where a genetic alteration is found, in order to ascertain whether this alteration is associated with disease risk.
  • To collect tissue samples from unaffected family members who show an interest in taking part in the study.

OUTLINE: Patients are assessed by a family history and epidemiology questionnaire and undergo a medical record review.

Patients and relatives with prostate cancer may undergo blood sample collection for genetic analysis of prostate cancer predisposition genes and measurement of markers of associations with genetic changes associated with prostate cancer. Blood and tumor samples are stored for future studies.


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Meets 1 of the following criteria:

    • Diagnosis of prostate cancer meeting any of the following criteria:

      • Attending prostate clinics at The Royal Marsden NHS Foundation Trust

        • Any age at diagnosis
      • Not attending prostate clinics at The Royal Marsden NHS Foundation Trust, meeting 1 of the following criteria:

        • No older than 60 years at diagnosis
        • Diagnosis in two relatives where one is ≤ 65 years at diagnosis
        • At any age in a cluster with 3 or more cases
    • Any unaffected male relatives of men who are already taking part in the study


  • Able to understand the information sheet and give informed consent
  • No man who is too ill to take part


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00959023

  Show 135 Study Locations
Sponsors and Collaborators
Institute of Cancer Research, United Kingdom
Principal Investigator: Rosalind Eeles, PhD, FRCR, FRCP, FMed Sci Royal Marsden NHS Foundation Trust
  More Information Identifier: NCT00959023     History of Changes
Other Study ID Numbers: CDR0000636371  ICR-UKGPCS  EU-20909 
Study First Received: August 13, 2009
Last Updated: August 23, 2013
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
stage I prostate cancer
stage IIB prostate cancer
stage IIA prostate cancer
stage III prostate cancer
stage IV prostate cancer
recurrent prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases processed this record on October 27, 2016